Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
3.24 x 3 3.33 x 9
Post-market by (Cboe BZX)
3.23 -0.28 (-7.98%) 04/04/25 [NASDAQ]
3.24 x 3 3.33 x 9
Post-market 3.36 +0.13 (+4.02%) 17:21 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.17
Day High
3.45
Open 3.41
Previous Close 3.51 3.51
Volume 1,537,400 1,537,400
Avg Vol 1,070,095 1,070,095
Stochastic %K 57.04% 57.04%
Weighted Alpha -2.52 -2.52
5-Day Change -0.27 (-7.71%) -0.27 (-7.71%)
52-Week Range 2.63 - 4.72 2.63 - 4.72
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 672,095
  • Shares Outstanding, K 191,480
  • Annual Sales, $ 6,170 K
  • Annual Income, $ -69,920 K
  • EBIT $ -76 M
  • EBITDA $ -75 M
  • 60-Month Beta 1.45
  • Price/Sales 108.91
  • Price/Cash Flow N/A
  • Price/Book 6.83

Options Overview Details

View History
  • Implied Volatility 60.98% ( -63.38%)
  • Historical Volatility 47.46%
  • IV Percentile 49%
  • IV Rank 10.42%
  • IV High 443.77% on 08/05/24
  • IV Low 16.46% on 05/21/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 214
  • Volume Avg (30-Day) 985
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 28,804
  • Open Int (30-Day) 24,303

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.02 +6.95%
on 03/12/25
Period Open: 3.39
3.61 -10.53%
on 04/02/25
-0.16 (-4.72%)
since 03/04/25
3-Month
3.02 +6.95%
on 03/12/25
Period Open: 3.42
3.70 -12.70%
on 02/25/25
-0.19 (-5.56%)
since 01/03/25
52-Week
2.63 +22.81%
on 05/02/24
Period Open: 3.00
4.72 -31.64%
on 09/09/24
+0.23 (+7.67%)
since 04/04/24

Most Recent Stories

More News
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

ABUS : 3.23 (-7.98%)
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS : 3.23 (-7.98%)
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

ABUS : 3.23 (-7.98%)
Arbutus Provides 2025 Corporate and Financial Update

ABUS : 3.23 (-7.98%)
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

ABUS : 3.23 (-7.98%)
Arbutus Biopharma Reports 50% Functional Cure Rate in Phase 2a Clinical Trial for Chronic Hepatitis B Virus

Arbutus Biopharma reports 50% functional cure rate in HBeAg-negative patients with low HBsAg after IM-PROVE I trial.Quiver AI SummaryArbutus Biopharma Corporation announced promising results from its IM-PROVE...

ABUS : 3.23 (-7.98%)
Arbutus Biopharma and Barinthus Bio Report Encouraging Preliminary Results from Phase 2a IM-PROVE II Clinical Trial for Chronic Hepatitis B Virus

Imdusiran, VTP-300, and low-dose nivolumab demonstrated significant HBsAg reduction in a Phase 2a clinical trial for chronic hepatitis B.Quiver AI SummaryArbutus Biopharma and Barinthus Biotherapeutics...

ABUS : 3.23 (-7.98%)
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

ABUS : 3.23 (-7.98%)
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

ABUS : 3.23 (-7.98%)
Arbutus to Present at Jefferies London Healthcare Conference

ABUS : 3.23 (-7.98%)

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 3.68
2nd Resistance Point 3.56
1st Resistance Point 3.40
Last Price 3.23
1st Support Level 3.12
2nd Support Level 3.00
3rd Support Level 2.84

See More

52-Week High 4.72
Fibonacci 61.8% 3.92
Fibonacci 50% 3.68
Fibonacci 38.2% 3.43
Last Price 3.23
52-Week Low 2.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades